Apogenix Announces Oral and Poster Presentations at Upcoming
International Conferences
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will present an overview of its HERA-ligand technology platform for cancer immunotherapy at Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit, which is part of the 26th international Molecular Medicine Tri-Conference in San Francisco, CA, USA. In addition, the company will provide updates on three of its HERA-ligands in poster presentations at the AACR Annual Meeting 2019 in Atlanta, GA, USA.